Episcleral plaque radiotherapy for retinoblastoma

J. A. Shields, M. E. Giblin, C. L. Shields, Arnold Markoe, U. Karlsson, L. W. Brady, B. E. Amendola, R. Woodleigh

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The authors report their preliminary results of episcleral plaque radiotherapy (cobalt 60, iridium 192, ruthenium 106, and iodine 125 plaques) in 50 selected patients with retinoblastoma. There were 97 plaque applications to 51 affected eyes in these 50 patients. The plaque was used as primary treatment in 15 eyes and as secondary treatment after failure of external beam radiotherapy, photocoagulation, and/or cryotherapy in 36 eyes. Vitreous seeding of tumor cells was evident ophthalmoscopically in 49 of the 51 eyes, negating the possibility of ultimate success by further photocoagulation or cryotherapy. In 18 patients, the contralateral eye had been enucleated and the remaining eye was being considered for enucleation because all other treatment modalities had failed. In 2 of these 18 patients (11%), the remaining eye was salvaged with plaque radiotherapy and some vision was preserved. In 33 eyes with less advanced tumors, 31 had some degree of vitreous seeding by tumor cells. The eye has been retained in all 33 of these patients and useful vision preserved in most. On the basis of these preliminary observations, the authors conclude that plaque radiotherapy can be used successfully as a primary treatment for selected cases of unilateral or bilateral retinoblastoma or as a supplemental treatment after other treatment methods have failed. The current indications for plaque radiotherapy and its advantages over other therapeutic modalities are discussed.

Original languageEnglish
Pages (from-to)530-537
Number of pages8
JournalOphthalmology
Volume96
Issue number4
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Retinoblastoma
Radiotherapy
Cryotherapy
Light Coagulation
Therapeutics
Iridium
Neoplasms
Ruthenium
Cobalt
Treatment Failure
Iodine

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Shields, J. A., Giblin, M. E., Shields, C. L., Markoe, A., Karlsson, U., Brady, L. W., ... Woodleigh, R. (1989). Episcleral plaque radiotherapy for retinoblastoma. Ophthalmology, 96(4), 530-537.

Episcleral plaque radiotherapy for retinoblastoma. / Shields, J. A.; Giblin, M. E.; Shields, C. L.; Markoe, Arnold; Karlsson, U.; Brady, L. W.; Amendola, B. E.; Woodleigh, R.

In: Ophthalmology, Vol. 96, No. 4, 01.01.1989, p. 530-537.

Research output: Contribution to journalArticle

Shields, JA, Giblin, ME, Shields, CL, Markoe, A, Karlsson, U, Brady, LW, Amendola, BE & Woodleigh, R 1989, 'Episcleral plaque radiotherapy for retinoblastoma', Ophthalmology, vol. 96, no. 4, pp. 530-537.
Shields JA, Giblin ME, Shields CL, Markoe A, Karlsson U, Brady LW et al. Episcleral plaque radiotherapy for retinoblastoma. Ophthalmology. 1989 Jan 1;96(4):530-537.
Shields, J. A. ; Giblin, M. E. ; Shields, C. L. ; Markoe, Arnold ; Karlsson, U. ; Brady, L. W. ; Amendola, B. E. ; Woodleigh, R. / Episcleral plaque radiotherapy for retinoblastoma. In: Ophthalmology. 1989 ; Vol. 96, No. 4. pp. 530-537.
@article{65f28517bd6e4efd8727d872b78d9d1e,
title = "Episcleral plaque radiotherapy for retinoblastoma",
abstract = "The authors report their preliminary results of episcleral plaque radiotherapy (cobalt 60, iridium 192, ruthenium 106, and iodine 125 plaques) in 50 selected patients with retinoblastoma. There were 97 plaque applications to 51 affected eyes in these 50 patients. The plaque was used as primary treatment in 15 eyes and as secondary treatment after failure of external beam radiotherapy, photocoagulation, and/or cryotherapy in 36 eyes. Vitreous seeding of tumor cells was evident ophthalmoscopically in 49 of the 51 eyes, negating the possibility of ultimate success by further photocoagulation or cryotherapy. In 18 patients, the contralateral eye had been enucleated and the remaining eye was being considered for enucleation because all other treatment modalities had failed. In 2 of these 18 patients (11{\%}), the remaining eye was salvaged with plaque radiotherapy and some vision was preserved. In 33 eyes with less advanced tumors, 31 had some degree of vitreous seeding by tumor cells. The eye has been retained in all 33 of these patients and useful vision preserved in most. On the basis of these preliminary observations, the authors conclude that plaque radiotherapy can be used successfully as a primary treatment for selected cases of unilateral or bilateral retinoblastoma or as a supplemental treatment after other treatment methods have failed. The current indications for plaque radiotherapy and its advantages over other therapeutic modalities are discussed.",
author = "Shields, {J. A.} and Giblin, {M. E.} and Shields, {C. L.} and Arnold Markoe and U. Karlsson and Brady, {L. W.} and Amendola, {B. E.} and R. Woodleigh",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "96",
pages = "530--537",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Episcleral plaque radiotherapy for retinoblastoma

AU - Shields, J. A.

AU - Giblin, M. E.

AU - Shields, C. L.

AU - Markoe, Arnold

AU - Karlsson, U.

AU - Brady, L. W.

AU - Amendola, B. E.

AU - Woodleigh, R.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The authors report their preliminary results of episcleral plaque radiotherapy (cobalt 60, iridium 192, ruthenium 106, and iodine 125 plaques) in 50 selected patients with retinoblastoma. There were 97 plaque applications to 51 affected eyes in these 50 patients. The plaque was used as primary treatment in 15 eyes and as secondary treatment after failure of external beam radiotherapy, photocoagulation, and/or cryotherapy in 36 eyes. Vitreous seeding of tumor cells was evident ophthalmoscopically in 49 of the 51 eyes, negating the possibility of ultimate success by further photocoagulation or cryotherapy. In 18 patients, the contralateral eye had been enucleated and the remaining eye was being considered for enucleation because all other treatment modalities had failed. In 2 of these 18 patients (11%), the remaining eye was salvaged with plaque radiotherapy and some vision was preserved. In 33 eyes with less advanced tumors, 31 had some degree of vitreous seeding by tumor cells. The eye has been retained in all 33 of these patients and useful vision preserved in most. On the basis of these preliminary observations, the authors conclude that plaque radiotherapy can be used successfully as a primary treatment for selected cases of unilateral or bilateral retinoblastoma or as a supplemental treatment after other treatment methods have failed. The current indications for plaque radiotherapy and its advantages over other therapeutic modalities are discussed.

AB - The authors report their preliminary results of episcleral plaque radiotherapy (cobalt 60, iridium 192, ruthenium 106, and iodine 125 plaques) in 50 selected patients with retinoblastoma. There were 97 plaque applications to 51 affected eyes in these 50 patients. The plaque was used as primary treatment in 15 eyes and as secondary treatment after failure of external beam radiotherapy, photocoagulation, and/or cryotherapy in 36 eyes. Vitreous seeding of tumor cells was evident ophthalmoscopically in 49 of the 51 eyes, negating the possibility of ultimate success by further photocoagulation or cryotherapy. In 18 patients, the contralateral eye had been enucleated and the remaining eye was being considered for enucleation because all other treatment modalities had failed. In 2 of these 18 patients (11%), the remaining eye was salvaged with plaque radiotherapy and some vision was preserved. In 33 eyes with less advanced tumors, 31 had some degree of vitreous seeding by tumor cells. The eye has been retained in all 33 of these patients and useful vision preserved in most. On the basis of these preliminary observations, the authors conclude that plaque radiotherapy can be used successfully as a primary treatment for selected cases of unilateral or bilateral retinoblastoma or as a supplemental treatment after other treatment methods have failed. The current indications for plaque radiotherapy and its advantages over other therapeutic modalities are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0024588428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024588428&partnerID=8YFLogxK

M3 - Article

C2 - 2726184

AN - SCOPUS:0024588428

VL - 96

SP - 530

EP - 537

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -